Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to TradeZacks Investment Research • 12/25/23
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 millionGlobeNewsWire • 12/21/23
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic OpportunitiesGlobeNewsWire • 10/30/23
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual CongressGlobeNewsWire • 10/24/23
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/10/23
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-OncologyGlobeNewsWire • 08/01/23
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC TestingGlobeNewsWire • 07/19/23
MeiraGTx Holdings PLC (MGTX) Soars 8.2%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/29/23
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced XerostomiaGlobeNewsWire • 06/27/23
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, GlobeNewsWire • 06/22/23
Does MeiraGTx Holdings PLC (MGTX) Have the Potential to Rally 320.9% as Wall Street Analysts Expect?Zacks Investment Research • 06/02/23
Wall Street Analysts Predict a 314.29% Upside in MeiraGTx Holdings PLC (MGTX): Here's What You Should KnowZacks Investment Research • 05/17/23
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual MeetingGlobeNewsWire • 04/21/23
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational ResultsGlobeNewsWire • 03/14/23
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022GlobeNewsWire • 12/08/22
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/10/22
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual CongressGlobeNewsWire • 10/04/22
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)GlobeNewsWire • 10/01/22